Ritonavir

利托那韦

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRitonavir
Drug Alias NameRitonavirum利多那韦爱治威迈可欣Norvir +[9] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitors
TargetsHuman immunodeficiency virus type 1 protease
Therapy Area/IndicationsBreast NeoplasmsSarcoma, KaposiHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date1996/03/01
Country/TerritoryUnited StatesAustraliaEU +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbott LaboratoriesPhokam Pharmaceutical Import-Export Co LtdAbbvie Inc +[4] 
Inactive CompaniesUniversity Of California San FranciscoAscletis Pharma IncGlaxosmithkline Plc +[4] 
Active IndicationsHIV Infections
Inactive IndicationsBreast NeoplasmsSarcoma, Kaposi

Other Information

ATC CodeJ05AE03
Related LinksWikipediaDrugBankKEGG